03
Mar
Global healthcare major Abbott has partnered with Novo Nordisk India to commercialize Extensior®, broadening access to semaglutide (Ozempic®) for advanced type 2 diabetes management in India. Under the agreement, Abbott will market Novo Nordisk’s semaglutide under the brand name Extensior®, leveraging its strong nationwide distribution network. Extensior® is a second brand of Ozempic®, the world’s most prescribed GLP-1 receptor agonist. Approved as an adjunct to diet and exercise for adults with type 2 diabetes, it delivers significant HbA1c reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events. Semaglutide has been evaluated in over 44 clinical trials and…
